Sun Pharm Inds Inc Drug Patent Portfolio
Sun Pharm Inds Inc owns 5 orange book drugs protected by 22 US patents with Sezaby having the least patent protection, holding only 1 patent. And Levulan with maximum patent protection, holding 11 patents. Given below is the list of Sun Pharm Inds Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11857683 | Stabilization of phenobarbital sodium for injection | 07 Apr, 2042 | Active |
| US11919907 | Deuterated JAK inhibitor and uses thereof | 21 May, 2041 | Active |
| US10357567 | Methods for photodynamic therapy | 12 Jan, 2038 | Active |
| US11077192 | Methods for photodynamic therapy | 12 Jan, 2038 | Active |
| US11135293 | Methods for photodynamic therapy | 12 Jan, 2038 | Active |
| US11571478 | Methods for photodynamic therapy | 12 Jan, 2038 | Active |
| US11690914 | Methods for photodynamic therapy | 12 Jan, 2038 | Active |
| US10561659 | Treatment of hair loss disorders with deuterated JAK inhibitors | 04 May, 2037 | Active |
| US12076323 | Treatment of hair loss disorders with deuterated JAK inhibitors | 04 May, 2037 | Active |
| US10172802 | Oral pharmaceutical dosage forms of budesonide | 09 Sep, 2036 | Active |
| US9707182 | Oral pharmaceutical dosage forms of budesonide | 09 Sep, 2036 | Active |
| US7435427 | Pharmaceutical semi-solid composition of isotretinoin | 21 Sep, 2021 | Expired |
| US8367102 | Pharmaceutical semi-solid composition of isotretinoin | 21 Sep, 2021 | Expired |
| US8952064 | Pharmaceutical semi-solid composition of isotretinoin | 21 Sep, 2021 | Expired |
| US9078925 | Pharmaceutical semi-solid composition of isotretinoin | 21 Sep, 2021 | Expired |
| US9089534 | Pharmaceutical semi-solid composition of isotretinoin | 21 Sep, 2021 | Expired |
| US7723910 | Method of photodynamically diagnosing or treating a contoured surface | 17 Jun, 2019 | Expired |
| US6709446 | Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light | 01 May, 2018 | Expired |
| US8216289 | Illuminator for photodynamic therapy | 01 May, 2018 | Expired |
| US8758418 | Illuminator for photodynamic therapy | 01 May, 2018 | Expired |
| US5954703 | Method and apparatus for applying 5-aminolevulinic acid | 31 Oct, 2017 | Expired |
| US5079262 | Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid | 30 Sep, 2013 | Expired |
Latest Legal Activities on Sun Pharm Inds Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sun Pharm Inds Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2024 | US8367102 (Litigated) |
| Patent eGrant Notification | 02 Jan, 2024 | US11857683 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 02 Jan, 2024 | US11857683 |
|
Email Notification
Critical
| 02 Jan, 2024 | US11857683 |
| Recordation of Patent eGrant | 02 Jan, 2024 | US11857683 |
|
Recordation of Patent Grant Mailed
Critical
| 02 Jan, 2024 | US11857683 |
| Mail Patent eGrant Notification | 02 Jan, 2024 | US11857683 |
|
Email Notification
Critical
| 14 Dec, 2023 | US11857683 |
|
Issue Notification Mailed
Critical
| 13 Dec, 2023 | US11857683 |
| Dispatch to FDC | 29 Nov, 2023 | US11857683 |
|
Application Is Considered Ready for Issue
Critical
| 29 Nov, 2023 | US11857683 |
|
Issue Fee Payment Verified
Critical
| 17 Nov, 2023 | US11857683 |
|
Issue Fee Payment Received
Critical
| 17 Nov, 2023 | US11857683 |
| Response to Reasons for Allowance | 17 Nov, 2023 | US11857683 |
| Mail Acknowledgement of Priority Papers-Pub | 13 Oct, 2023 | US11857683 |
Sun Pharm Inds Inc's Drug Patent Litigations
Sun Pharm Inds Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 22, 2018, against patent number US8216289. The petitioner Biofrontera Incorporated, challenged the validity of this patent, with DUSA Pharmaceuticals Inc. as the respondent. Click below to track the latest information on how companies are challenging Sun Pharm Inds Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10357567 | October, 2021 |
Terminated
(24 Jan, 2022)
| DUSA Pharmaceuticals, Inc. et al. | Biofrontera Inc. et al. |
| US8216289 | August, 2018 |
Terminated-Denied
(26 Feb, 2019)
| DUSA Pharmaceuticals Inc. | Biofrontera Incorporated |
Sun Pharm Inds Inc's Family Patents
Sun Pharm Inds Inc Drug List
Given below is the complete list of Sun Pharm Inds Inc's drugs and the patents protecting them.
1. Absorica
Absorica is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7435427 | Pharmaceutical semi-solid composition of isotretinoin |
21 Sep, 2021
(3 years ago)
| Expired |
| US8367102 | Pharmaceutical semi-solid composition of isotretinoin |
21 Sep, 2021
(3 years ago)
| Expired |
| US8952064 | Pharmaceutical semi-solid composition of isotretinoin |
21 Sep, 2021
(3 years ago)
| Expired |
| US9078925 | Pharmaceutical semi-solid composition of isotretinoin |
21 Sep, 2021
(3 years ago)
| Expired |
| US9089534 | Pharmaceutical semi-solid composition of isotretinoin |
21 Sep, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Absorica's drug page
2. Leqselvi
Leqselvi is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11919907 | Deuterated JAK inhibitor and uses thereof |
21 May, 2041
(16 years from now)
| Active |
| US10561659 | Treatment of hair loss disorders with deuterated JAK inhibitors |
04 May, 2037
(11 years from now)
| Active |
| US12076323 | Treatment of hair loss disorders with deuterated JAK inhibitors |
04 May, 2037
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Leqselvi's drug page
3. Levulan
Levulan is protected by 11 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10357567 | Methods for photodynamic therapy |
12 Jan, 2038
(12 years from now)
| Active |
| US11077192 | Methods for photodynamic therapy |
12 Jan, 2038
(12 years from now)
| Active |
| US11135293 | Methods for photodynamic therapy |
12 Jan, 2038
(12 years from now)
| Active |
| US11571478 | Methods for photodynamic therapy |
12 Jan, 2038
(12 years from now)
| Active |
| US11690914 | Methods for photodynamic therapy |
12 Jan, 2038
(12 years from now)
| Active |
| US7723910 | Method of photodynamically diagnosing or treating a contoured surface |
17 Jun, 2019
(5 years ago)
| Expired |
| US6709446 | Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light |
01 May, 2018
(7 years ago)
| Expired |
| US8216289 | Illuminator for photodynamic therapy |
01 May, 2018
(7 years ago)
| Expired |
| US8758418 | Illuminator for photodynamic therapy |
01 May, 2018
(7 years ago)
| Expired |
| US5954703 | Method and apparatus for applying 5-aminolevulinic acid |
31 Oct, 2017
(7 years ago)
| Expired |
| US5079262 | Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid |
30 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levulan's drug page
4. Ortikos
Ortikos is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10172802 | Oral pharmaceutical dosage forms of budesonide |
09 Sep, 2036
(11 years from now)
| Active |
| US9707182 | Oral pharmaceutical dosage forms of budesonide |
09 Sep, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ortikos's drug page
5. Sezaby
Sezaby is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11857683 | Stabilization of phenobarbital sodium for injection |
07 Apr, 2042
(16 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sezaby's drug page